Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Lavallard, Vanessa Jeannette ^a,b,c   Bonnafous, Stéphanie ^a,c   Patouraux, Stéphanie ^a,b,c   Saint Paul, Marie Christine ^a,b,c   Rousseau, Déborah ^a,b   Anty, Rodolphe ^a,b,c   Le Marchand Brustel, Yannick ^a,b,c   Tran, Albert ^a,b,c   Gual, Philippe ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; BIOLOGICAL MARKER; CYTOKERATIN 18; FAS LIGAND; HYALURONIC ACID; PROTHROMBIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL LIVER DISEASE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL DAMAGE; LIVER FIBROSIS; MALE; MALLORY BODY; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; UPREGULATION; BLOOD; LIVER CELL; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; APOPTOSIS; BIOLOGICAL MARKERS; FEMALE; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952796670     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017599     Document Type: Article

References (36)

1. Lucey MR, Mathurin P, Morgan TR, (2009) Alcoholic hepatitis. N Engl J Med 360: 2758-2769.
2. Feldstein AE, Gores GJ, (2005) Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 10: 3093-3099.
3. Malhi H, Gores GJ, (2008) Cellular and molecular mechanisms of liver injury. Gastroenterology 134: 1641-1654.
4. Taieb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S, (1998) Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 351: 1930-1931.
5. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI, (1991) Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13: 267-276.
6. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, et al. (2001) Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 34: 248-253.
7. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, et al. (2004) Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99: 1708-1717.
8. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, et al. (1995) Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182: 1223-1230.
9. Jaeschke H, Lemasters JJ, (2003) Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125: 1246-1257.
10. Linder S, Havelka AM, Ueno T, Shoshan MC, (2004) Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214: 1-9.
11. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, et al. (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751-1756.
12. Luft T, Conzelmann M, Benner A, Rieger M, Hess M, et al. (2007) Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 110: 4535-4542.
13. Yilmaz Y, (2009) Systematic review: caspase-cleaved fragments of cytokeratin 18- the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 30: 1103-1109.
14. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, et al. (2006) In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44: 27-33.
15. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, et al. (2008) A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18: 1430-1437.
16. Diab DL, Yerian L, Schauer P, Kashyap SR, Lopez R, et al. (2008) Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol 6: 1249-1254.
17. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, et al. (2009) Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50: 1072-1078.
18. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, et al. (2010) Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 59: 969-974.
19. Gonzalez-Quintela A, Abdulkader I, Campos J, Fernandez-Hernandez L, Lojo S, (2009) Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 54: 648-653.
20. Gonzalez-Quintela A, Garcia J, Campos J, Perez LF, Alende MR, et al. (2006) Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol 38: 45-49.
21. Li X, Zhang Y, Wu K, Fan D, (2010) Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis. Hepatology 51: 1865-1866.
22. Gonzalez-Quintela A, Mallo N, Mella C, Campos J, Perez LF, et al. (2006) Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases. Liver Int 26: 1217-1224.
23. Orrego H, Blake JE, Blendis LM, Medline A, (1987) Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 92: 208-214.
24. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, et al. (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: 3198-3206.
25. Bekri S, Gual P, Anty R, Luciani N, Dahman M, et al. (2006) Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 131: 788-796.
26. Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, et al. (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 58: 125-133.
27. Purohit V, Brenner DA, (2006) Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43: 872-878.
28. Bataller R, Brenner DA, (2005) Liver fibrosis. J Clin Invest 115: 209-218.
29. Caulin C, Salvesen GS, Oshima RG, (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138: 1379-1394.
30. Manning DS, Afdhal NH, (2008) Diagnosis and quantitation of fibrosis. Gastroenterology 134: 1670-1681.
31. Naveau S, Gaude G, Asnacios A, Agostini H, Abella A, et al. (2009) Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49: 97-105.
32. Nguyen-Khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, et al. (2008) Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 28: 1188-1198.
33. Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, et al. (2010) Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 53: 639-647.
34. Anty R, Iannelli A, Patouraux S, Bonnafous S, Lavallard VJ, et al. (2010) A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther 32: 1315-1322.
35. Feldstein A, Kleiner D, Kravetz D, Buck M, (2009) Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor. J Clin Gastroenterol 43: 374-381.
36. Volkmann X, Cornberg M, Wedemeyer H, Lehner F, Manns MP, et al. (2006) Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 43: 1311-1316.